Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy

Results of an open, follow-up pilot study

J. Gaál, Gabriella Lakos, Péter Szodoray, Judit Kiss, Irén Horváth, Edit Horkay, Georgina Nagy, A. Szegedi

Research output: Article

27 Citations (Scopus)

Abstract

The aim of this study was to describe the effect of systemic alphacalcidol (1αOH vitamin D3) treatment on clinical and immunological parameters in patients with psoriatic arthropathy. Among the 19 patients investigated, 10 were treated with 0.25 μg oral alphacalcidol twice daily for 6 months, while 9 other patients served as controls. In the peripheral blood of the treated group but not in the controls, a statistically significant decrease was observed in the percentage of CD3/CD69-positive activated and CD8-positive interferon-γ-producing T cells and in the serum level of interferon-γ during the first 3 months and also in the clinical activity of the disease during the whole 6-month follow-up period. Our results show that systemic alphacalcidol treatment has an immunomodulatory effect on patients with psoriatic arthropathy. This effect is manifested by a short-term temporary decrease in type 1 immune responses and a continuous decrease in disease activity.

Original languageEnglish
Pages (from-to)140-144
Number of pages5
JournalActa Dermato-Venereologica
Volume89
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

Psoriatic Arthritis
Interferons
Cholecalciferol
Blood Group Antigens
T-Lymphocytes
alfacalcidol
Therapeutics
Serum

ASJC Scopus subject areas

  • Dermatology

Cite this

Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy : Results of an open, follow-up pilot study. / Gaál, J.; Lakos, Gabriella; Szodoray, Péter; Kiss, Judit; Horváth, Irén; Horkay, Edit; Nagy, Georgina; Szegedi, A.

In: Acta Dermato-Venereologica, Vol. 89, No. 2, 2009, p. 140-144.

Research output: Article

Gaál, J. ; Lakos, Gabriella ; Szodoray, Péter ; Kiss, Judit ; Horváth, Irén ; Horkay, Edit ; Nagy, Georgina ; Szegedi, A. / Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy : Results of an open, follow-up pilot study. In: Acta Dermato-Venereologica. 2009 ; Vol. 89, No. 2. pp. 140-144.
@article{771d46cd4dc74b42bdf4764726c44d97,
title = "Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy: Results of an open, follow-up pilot study",
abstract = "The aim of this study was to describe the effect of systemic alphacalcidol (1αOH vitamin D3) treatment on clinical and immunological parameters in patients with psoriatic arthropathy. Among the 19 patients investigated, 10 were treated with 0.25 μg oral alphacalcidol twice daily for 6 months, while 9 other patients served as controls. In the peripheral blood of the treated group but not in the controls, a statistically significant decrease was observed in the percentage of CD3/CD69-positive activated and CD8-positive interferon-γ-producing T cells and in the serum level of interferon-γ during the first 3 months and also in the clinical activity of the disease during the whole 6-month follow-up period. Our results show that systemic alphacalcidol treatment has an immunomodulatory effect on patients with psoriatic arthropathy. This effect is manifested by a short-term temporary decrease in type 1 immune responses and a continuous decrease in disease activity.",
keywords = "Alphacalcidol treatment, Immunomodulatory effect, Psoriatic arthropathy",
author = "J. Ga{\'a}l and Gabriella Lakos and P{\'e}ter Szodoray and Judit Kiss and Ir{\'e}n Horv{\'a}th and Edit Horkay and Georgina Nagy and A. Szegedi",
year = "2009",
doi = "10.2340/00015555-0555",
language = "English",
volume = "89",
pages = "140--144",
journal = "Acta Dermato-Venereologica",
issn = "0001-5555",
publisher = "Society for the Publication of Acta Dermato-Venereologica",
number = "2",

}

TY - JOUR

T1 - Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy

T2 - Results of an open, follow-up pilot study

AU - Gaál, J.

AU - Lakos, Gabriella

AU - Szodoray, Péter

AU - Kiss, Judit

AU - Horváth, Irén

AU - Horkay, Edit

AU - Nagy, Georgina

AU - Szegedi, A.

PY - 2009

Y1 - 2009

N2 - The aim of this study was to describe the effect of systemic alphacalcidol (1αOH vitamin D3) treatment on clinical and immunological parameters in patients with psoriatic arthropathy. Among the 19 patients investigated, 10 were treated with 0.25 μg oral alphacalcidol twice daily for 6 months, while 9 other patients served as controls. In the peripheral blood of the treated group but not in the controls, a statistically significant decrease was observed in the percentage of CD3/CD69-positive activated and CD8-positive interferon-γ-producing T cells and in the serum level of interferon-γ during the first 3 months and also in the clinical activity of the disease during the whole 6-month follow-up period. Our results show that systemic alphacalcidol treatment has an immunomodulatory effect on patients with psoriatic arthropathy. This effect is manifested by a short-term temporary decrease in type 1 immune responses and a continuous decrease in disease activity.

AB - The aim of this study was to describe the effect of systemic alphacalcidol (1αOH vitamin D3) treatment on clinical and immunological parameters in patients with psoriatic arthropathy. Among the 19 patients investigated, 10 were treated with 0.25 μg oral alphacalcidol twice daily for 6 months, while 9 other patients served as controls. In the peripheral blood of the treated group but not in the controls, a statistically significant decrease was observed in the percentage of CD3/CD69-positive activated and CD8-positive interferon-γ-producing T cells and in the serum level of interferon-γ during the first 3 months and also in the clinical activity of the disease during the whole 6-month follow-up period. Our results show that systemic alphacalcidol treatment has an immunomodulatory effect on patients with psoriatic arthropathy. This effect is manifested by a short-term temporary decrease in type 1 immune responses and a continuous decrease in disease activity.

KW - Alphacalcidol treatment

KW - Immunomodulatory effect

KW - Psoriatic arthropathy

UR - http://www.scopus.com/inward/record.url?scp=63049126065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63049126065&partnerID=8YFLogxK

U2 - 10.2340/00015555-0555

DO - 10.2340/00015555-0555

M3 - Article

VL - 89

SP - 140

EP - 144

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

SN - 0001-5555

IS - 2

ER -